# Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3

> **NCT02227823** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Régional de la Citadelle** · enrollment: 4 (actual)

## Conditions studied

- Spinal Muscular Atrophy Type 3

## Interventions

- **DRUG:** Pyridostigmine Bromide

## Key facts

- **NCT ID:** NCT02227823
- **Lead sponsor:** Centre Hospitalier Régional de la Citadelle
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227823, "Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02227823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*